ITGA3 and prostate carcinoma: Through our simple NPs-based assay, we reaffirmed their findings by showing higher expression of ITGA3 on the EVs obtained from more aggressive prostate cancer cell lines DU145 and PC3 compared to the less aggressive prostate cancer cell line LNCaP and HEK293 control.